BioNTech (BNTX) Financials

$102.34 +5.82 (+6.03%)

As of 04/14/2025 04:00 PM Eastern

Annual Income Statements for BioNTech

This table shows BioNTech's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-103	-55	-201	19	11,649	10,093	1,029	-689
Consolidated Net Income / (Loss)	-103	-55	-201	19	11,649	10,093	1,029	-689
Net Income / (Loss) Continuing Operations	-103	-55	-201	19	11,649	10,093	1,029	-689
Total Pre-Tax Income	-103	-55	-201	-178	17,030	13,858	1,312	-701
Total Operating Income	-74	-62	-204	-101	17,298	13,525	764	-1,360
Total Gross Profit	63	130	102	517	18,183	15,315	3,561	2,287
Total Revenue	74	146	122	589	21,478	18,519	4,225	2,848
Operating Revenue	74	146	122	589	21,478	18,519	4,225	2,848
Total Cost of Revenue	11	16	20	72	3,295	3,204	663	560
Operating Cost of Revenue	11	16	20	72	3,295	3,204	663	560
Total Operating Expenses	136	192	305	617	884	1,790	2,797	3,648
Selling, General & Admin Expense	28	30	51	115	313	515	548	550
Marketing Expense	7.93	3.48	3.03	18	57	64	69	70
Research & Development Expense	103	164	254	788	1,074	1,644	1,972	2,333
Other Operating Expenses / (Income)	-2.48	-5.35	-2.24	-303	-560	-434	208	694
Total Other Income / (Expense), net	-30	7.09	2.36	-77	-269	333	548	659
Interest Expense	32	2.02	2.24	79	345	20	26	28
Interest & Investment Income	2.56	9.21	4.60	1.95	77	353	575	687
Income Tax Expense	0.05	0.69	-0.22	-197	5,380	3,765	283	-13
Basic Earnings per Share	($0.61)	($0.25)	($0.85)	$0.06	$42.18	$41.49	$4.28	($2.87)
Weighted Average Basic Shares Outstanding	-	-	-	241.52B	246.81M	240.99M	237.73M	239.97M
Diluted Earnings per Share	($0.61)	($0.25)	($0.85)	$0.06	$39.63	$40.41	$4.24	($2.87)
Weighted Average Diluted Shares Outstanding	-	-	-	241.52B	246.81M	240.99M	237.73M	239.97M
Weighted Average Basic & Diluted Shares Outstanding	-	-	-	241.52B	246.81M	240.99M	237.73M	239.97M

No quarterly income statements for BioNTech are available.

This table details how cash moves in and out of BioNTech's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-128	275	121	900	473	13,033	6,313	809
Net Cash From Operating Activities	-63	-67	-223	-16	1,007	13,404	1,558	410
Net Cash From Continuing Operating Activities	-58	-67	-223	-16	1,022	13,404	1,558	410
Net Income / (Loss) Continuing Operations	-103	-55	-201	-178	17,030	10,093	1,029	-689
Consolidated Net Income / (Loss)	-103	-55	-201	-178	17,030	10,093	1,029	-689
Depreciation Expense	13	25	38	47	85	132	203	308
Non-Cash Adjustments To Reconcile Net Income	35	9.09	35	230	-22	3,088	194	4.76
Changes in Operating Assets and Liabilities, net	-2.44	-47	-94	-116	-16,071	91	132	785
Net Cash From Investing Activities	-63	-76	-87	-177	-641	50	5,572	401
Net Cash From Continuing Investing Activities	-23	-76	-87	-177	-622	50	5,572	401
Acquisitions	0.00	0.00	-6.85	-74	-24	0.00	-373	0.00
Sale of Property, Plant & Equipment	6.24	0.81	0.00	1.47	-	0.64	5,945	401
Net Cash From Financing Activities	-1.97	418	430	1,093	107	99	-817	-2.38
Net Cash From Continuing Financing Activities	-1.97	418	430	1,093	107	99	-817	-2.38
Repayment of Debt	-1.97	-2.46	-3.48	-17	-75	-20	-0.11	-2.38
Repurchase of Preferred Equity	-	-	-	-	0.00	-	-817	0.00
Issuance of Debt	0.00	6.41	12	191	0.00	0.86	0.33	0.00

No quarterly cash flow statements for BioNTech are available.

This table presents BioNTech's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024
Total Assets	747	895	2,832	17,917	24,904	25,450	23,320
Total Current Assets	514	629	2,036	17,059	23,452	21,601	19,464
Cash & Equivalents	471	583	1,478	1,916	14,844	12,902	10,105
Accounts Receivable	22	13	202	14,014	7,644	2,385	1,515
Inventories, net	6.63	13	78	569	470	396	293
Current Deferred & Refundable Income Taxes	1.02	0.85	1.10	0.45	0.43	198	52
Other Current Assets	13	17	276	128	291	316	231
Other Current Nonoperating Assets	0.38	1.89	-	432	203	5,404	7,268
Plant, Property, & Equipment, net	76	104	277	365	652	838	968
Plant, Property & Equipment, gross	76	104	277	365	652	838	968
Total Noncurrent Assets	158	162	519	493	800	3,011	2,889
Goodwill	-	-	-	-	65	401	394
Intangible Assets	101	100	200	229	170	889	818
Noncurrent Deferred & Refundable Income Taxes	-	0.00	197	0.00	246	90	85
Other Noncurrent Operating Assets	57	62	122	264	319	1,630	1,592
Total Liabilities & Shareholders' Equity	747	895	2,832	17,917	24,904	25,450	23,320
Total Liabilities	442	341	1,157	4,456	3,449	3,054	3,228
Total Current Liabilities	144	155	740	3,940	3,157	2,290	2,612
Short-Term Debt	9.46	5.96	11	-	840	459	1,494
Accounts Payable	48	23	125	181	218	392	442
Current Deferred & Payable Income Tax Liabilities	0.34	0.17	0.00	1,776	637	581	4.66
Other Current Liabilities	87	126	604	1,984	1,461	858	671
Total Noncurrent Liabilities	297	186	416	516	292	763	616
Long-Term Debt	-	77	282	-	6.53	43	49
Capital Lease Obligations	-	-	-	194	188	211	222
Noncurrent Deferred & Payable Income Tax Liabilities	-	0.00	0.24	80	18	44	44
Other Noncurrent Operating Liabilities	297	109	134	241	79	465	302
Total Equity & Noncontrolling Interests	306	554	1,676	13,461	21,455	22,396	20,092
Total Preferred & Common Equity	305	554	1,676	13,461	21,455	22,396	20,092
Total Common Equity	305	554	1,676	13,461	21,455	22,396	20,092
Common Stock	221	261	301	279	266	275	257
Retained Earnings	-	-	-500	11,185	20,148	21,862	19,768
Treasury Stock	0.00	-6.20	-5.86	-4.30	-5.67	-12	-8.90
Other Equity Adjustments	365	776	1,881	2,001	1,048	271	76

No quarterly balance sheets for BioNTech are available.

This table displays calculated financial ratios and metrics derived from BioNTech's official financial filings.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	97.33%	-16.53%	383.42%	3,545.38%	-13.78%	-77.19%	-32.59%
EBITDA Growth	0.00%	40.10%	-352.93%	67.77%	32,662.70%	-21.44%	-92.92%	-208.83%
EBIT Growth	0.00%	16.24%	-229.96%	50.58%	17,284.74%	-21.81%	-94.35%	-278.13%
NOPAT Growth	0.00%	16.26%	-230.47%	50.58%	16,893.19%	-16.75%	-93.92%	-258.98%
Net Income Growth	0.00%	46.50%	-264.09%	109.23%	62,635.91%	-13.36%	-89.80%	-166.92%
EPS Growth	0.00%	50.98%	-240.00%	107.06%	65,950.00%	1.96%	-89.51%	-167.68%
Operating Cash Flow Growth	0.00%	-6.72%	-230.59%	92.60%	6,205.89%	1,231.12%	-88.38%	-73.70%
Free Cash Flow Firm Growth	0.00%	0.00%	-394.99%	-41.05%	299.73%	1,250.12%	-76.37%	-119.56%
Invested Capital Growth	0.00%	0.00%	131.81%	832.84%	2,204.34%	-34.17%	-35.48%	-6.63%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	84.87%	89.27%	83.98%	87.70%	84.66%	82.70%	84.29%	80.32%
EBITDA Margin	-82.51%	-25.05%	-135.91%	-9.06%	80.94%	73.75%	22.88%	-36.94%
Operating Margin	-99.48%	-42.21%	-167.13%	-17.08%	80.54%	73.03%	18.08%	-47.77%
EBIT Margin	-99.61%	-42.28%	-167.13%	-17.08%	80.54%	73.03%	18.08%	-47.77%
Profit (Net Income) Margin	-139.53%	-37.83%	-165.01%	3.15%	54.24%	54.50%	24.36%	-24.18%
Tax Burden Percent	100.05%	101.26%	99.89%	-10.43%	68.41%	72.83%	78.43%	98.17%
Interest Burden Percent	140.01%	88.36%	98.84%	176.94%	98.45%	102.46%	171.80%	51.56%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	31.59%	27.17%	21.57%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	-25.94%	200.58%	105.06%	9.78%	-20.51%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	-36.50%	211.59%	102.06%	7.06%	-22.10%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	27.60%	-46.67%	-47.25%	-5.09%	17.27%
Return on Equity (ROE)	0.00%	-18.02%	-46.75%	1.67%	153.91%	57.81%	4.69%	-3.24%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-685.42%	-187.21%	17.22%	146.27%	52.91%	-13.65%
Operating Return on Assets (OROA)	0.00%	-8.26%	-24.80%	-5.40%	166.73%	63.17%	3.03%	-5.58%
Return on Assets (ROA)	0.00%	-7.39%	-24.49%	1.00%	112.28%	47.14%	4.09%	-2.82%
Return on Common Equity (ROCE)	0.00%	-17.90%	-46.64%	1.67%	153.91%	57.81%	4.69%	-3.24%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-18.08%	-36.31%	1.11%	86.54%	47.04%	4.60%	-3.43%
Net Operating Profit after Tax (NOPAT)	-52	-43	-143	-70	11,833	9,850	599	-952
NOPAT Margin	-69.64%	-29.55%	-116.99%	-11.96%	55.09%	53.19%	14.18%	-33.44%
Net Nonoperating Expense Percent (NNEP)	0.00%	-5.12%	-12.03%	10.56%	-11.01%	3.00%	2.72%	1.59%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	43.80%	2.59%	-4.36%
Cost of Revenue to Revenue	15.13%	10.73%	16.02%	12.30%	15.34%	17.30%	15.71%	19.68%
SG&A Expenses to Revenue	38.18%	20.64%	41.90%	19.49%	1.46%	2.78%	12.96%	19.31%
R&D to Revenue	138.80%	112.12%	208.56%	133.73%	5.00%	8.88%	46.69%	81.94%
Operating Expenses to Revenue	184.35%	131.48%	250.46%	104.79%	4.12%	9.66%	66.22%	128.10%
Earnings before Interest and Taxes (EBIT)	-74	-62	-204	-101	17,298	13,525	764	-1,360
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-61	-37	-166	-53	17,383	13,657	967	-1,052
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.49	0.60	10.89	4.57	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.74	0.74	12.36	4.64	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.03	1.03	2.74	30.97	2.86	0.00	0.01	0.01
Price to Earnings (P/E)	0.00	0.00	0.00	982.61	5.28	0.00	0.02	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	1.42%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.10%	18.96%	27,222.64%	4,046.07%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	34.77	5.28	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	28.96	2.78	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	3.44	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	3.45	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	5.05	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	59.32	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	58.80	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.15	0.18	0.01	0.05	0.03	0.09
Long-Term Debt to Equity	0.00	0.00	0.14	0.17	0.01	0.01	0.01	0.01
Financial Leverage	0.00	-1.54	-1.13	-0.76	-0.22	-0.46	-0.72	-0.78
Leverage Ratio	0.00	2.44	1.91	1.67	1.37	1.23	1.15	1.15
Compound Leverage Factor	0.00	2.15	1.89	2.96	1.35	1.26	1.97	0.59
Debt to Total Capital	0.00%	0.00%	13.07%	14.90%	1.42%	4.60%	3.09%	8.07%
Short-Term Debt to Total Capital	0.00%	0.00%	0.93%	0.56%	0.00%	3.73%	1.99%	6.84%
Long-Term Debt to Total Capital	0.00%	0.00%	12.14%	14.33%	1.42%	0.87%	1.10%	1.24%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.32%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	99.37%	86.93%	85.10%	98.58%	95.40%	96.91%	91.93%
Debt to EBITDA	0.00	0.00	-0.50	-5.49	0.01	0.08	0.74	-1.68
Net Debt to EBITDA	0.00	0.00	3.01	22.20	-0.10	-1.01	-12.61	7.93
Long-Term Debt to EBITDA	0.00	0.00	-0.47	-5.29	0.01	0.01	0.26	-0.26
Debt to NOPAT	0.00	0.00	-0.58	-4.16	0.02	0.11	1.19	-1.85
Net Debt to NOPAT	0.00	0.00	3.50	16.82	-0.15	-1.40	-20.35	8.76
Long-Term Debt to NOPAT	0.00	0.00	-0.54	-4.00	0.02	0.02	0.42	-0.28
Altman Z-Score	0.00	0.72	0.61	9.86	14.41	4.65	2.38	1.99
Noncontrolling Interest Sharing Ratio	0.00%	0.63%	0.23%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	0.00	3.56	4.05	2.75	4.33	7.43	9.43	7.45
Quick Ratio	0.00	3.41	3.84	2.27	4.04	7.12	6.67	4.45
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	122	-361	-509	1,016	13,714	3,240	-634
Operating Cash Flow to CapEx	-274.81%	-201.66%	-279.18%	-16.03%	577.73%	3,812.93%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	60.37	-160.64	-6.40	2.94	678.26	122.56	-22.35
Operating Cash Flow to Interest Expense	-1.97	-33.28	-99.25	-0.21	2.92	662.93	58.92	14.44
Operating Cash Flow Less CapEx to Interest Expense	-2.69	-49.79	-134.80	-1.50	2.41	645.54	283.77	28.59
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.20	0.15	0.32	2.07	0.86	0.17	0.12
Accounts Receivable Turnover	0.00	6.74	6.96	5.47	3.02	1.71	0.84	1.46
Inventory Turnover	0.00	2.36	1.97	1.58	10.19	6.17	1.53	1.63
Fixed Asset Turnover	0.00	1.93	1.35	3.09	66.88	36.43	5.67	3.15
Accounts Payable Turnover	0.00	0.33	0.55	0.98	21.53	16.04	2.18	1.34
Days Sales Outstanding (DSO)	0.00	54.18	52.48	66.77	120.79	213.44	433.25	249.94
Days Inventory Outstanding (DIO)	0.00	154.35	184.87	230.41	35.83	59.18	238.19	224.40
Days Payable Outstanding (DPO)	0.00	1,112.36	661.26	372.79	16.95	22.75	167.77	271.41
Cash Conversion Cycle (CCC)	0.00	-903.83	-423.92	-75.61	139.68	249.87	503.67	202.92
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	0.00	-165	53	491	11,308	7,444	4,803	4,485
Invested Capital Turnover	0.00	-1.77	-2.16	2.17	3.64	1.98	0.69	0.61
Increase / (Decrease) in Invested Capital	0.00	-165	218	438	10,817	-3,864	-2,641	-318
Enterprise Value (EV)	0.00	-320	-165	17,060	59,729	-13,772	-12,163	-8,313
Market Capitalization	150	150	334	18,245	61,450	37	25	27
Book Value per Share	$0.00	$30.46	$55.38	$0.01	$0.06	$86.93	$92.93	$84.52
Tangible Book Value per Share	$0.00	$20.39	$45.35	$0.01	$0.05	$85.98	$87.58	$79.42
Total Capital	0.00	307	637	1,969	13,656	22,490	23,110	21,857
Total Debt	0.00	0.00	83	293	194	1,035	713	1,765
Total Long-Term Debt	0.00	0.00	77	282	194	195	254	271
Net Debt	0.00	-471	-499	-1,185	-1,722	-13,809	-12,189	-8,340
Capital Expenditures (CapEx)	23	33	80	103	174	352	-5,945	-401
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-101	-103	-171	11,203	6,292	6,868	8,241
Debt-free Net Working Capital (DFNWC)	0.00	369	480	1,307	13,118	21,136	19,770	18,346
Net Working Capital (NWC)	0.00	369	474	1,296	13,118	20,296	19,311	16,852
Net Nonoperating Expense (NNE)	52	12	59	-89	184	-243	-430	-264
Net Nonoperating Obligations (NNO)	0.00	-472	-501	-1,185	-2,153	-14,011	-17,593	-15,608
Total Depreciation and Amortization (D&A)	13	25	38	47	85	132	203	308
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-69.49%	-84.56%	-29.07%	52.16%	33.98%	162.56%	289.40%
Debt-free Net Working Capital to Revenue	0.00%	253.06%	393.48%	221.85%	61.08%	114.13%	467.98%	644.24%
Net Working Capital to Revenue	0.00%	253.06%	388.59%	219.97%	61.08%	109.59%	457.10%	591.77%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($0.85)	$0.06	$0.00	$38.78	$3.87	($2.87)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	0.00	241.52B	0.00	240.99M	237.73M	239.97M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($0.85)	$0.06	$0.00	$37.77	$3.83	($2.87)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	0.00	241.52B	0.00	240.99M	237.73M	239.97M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($0.85)	$0.06	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	0.00	241.52B	0.00	240.99M	237.73M	239.97M
Normalized Net Operating Profit after Tax (NOPAT)	-52	-43	-143	-70	11,833	9,850	599	-952
Normalized NOPAT Margin	-69.64%	-29.55%	-116.99%	-11.96%	55.09%	53.19%	14.18%	-33.44%
Pre Tax Income Margin	-139.46%	-37.36%	-165.19%	-30.23%	79.29%	74.83%	31.06%	-24.63%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-2.30	-30.49	-90.75	-1.27	50.09	668.93	28.89	-47.97
NOPAT to Interest Expense	-1.61	-21.31	-63.53	-0.89	34.27	487.18	22.66	-33.58
EBIT Less CapEx to Interest Expense	-3.02	-46.99	-126.30	-2.56	49.59	651.54	253.74	-33.82
NOPAT Less CapEx to Interest Expense	-2.32	-37.81	-99.08	-2.18	33.76	469.79	247.51	-19.43
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

No quarterly metrics and ratios for BioNTech are available.

Frequently Asked Questions About BioNTech's Financials

When does BioNTech's financial year end?

According to the most recent income statement we have on file, BioNTech's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has BioNTech's net income changed over the last 7 years?

BioNTech's net income appears to be on an upward trend, with a most recent value of -$688.65 million in 2024, rising from -$103.25 million in 2017. The previous period was $1.03 billion in 2023.

What is BioNTech's operating income?

BioNTech's total operating income in 2024 was -$1.36 billion, based on the following breakdown:

Total Gross Profit: $2.29 billion
Total Operating Expenses: $3.65 billion

How has BioNTech revenue changed over the last 7 years?

Over the last 7 years, BioNTech's total revenue changed from $73.99 million in 2017 to $2.85 billion in 2024, a change of 3,748.5%.

How much debt does BioNTech have?

BioNTech's total liabilities were at $3.23 billion at the end of 2024, a 5.7% increase from 2023, and a 630.7% increase since 2018.

How much cash does BioNTech have?

In the past 6 years, BioNTech's cash and equivalents has ranged from $470.96 million in 2018 to $14.84 billion in 2022, and is currently $10.10 billion as of their latest financial filing in 2024.

How has BioNTech's book value per share changed over the last 7 years?

Over the last 7 years, BioNTech's book value per share changed from 0.00 in 2017 to 84.52 in 2024, a change of 8,451.9%.

Remove Ads

Related Companies

This page (NASDAQ:BNTX) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioNTech (BNTX) Financials

Frequently Asked Questions About BioNTech's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioNTech (BNTX) Financials

Annual Income Statements for BioNTech

Quarterly Income Statements for BioNTech

Annual Cash Flow Statements for BioNTech

Quarterly Cash Flow Statements for BioNTech

Annual Balance Sheets for BioNTech

Quarterly Balance Sheets for BioNTech

Annual Metrics and Ratios for BioNTech

Quarterly Metrics and Ratios for BioNTech

Frequently Asked Questions About BioNTech's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools